Skip to main content

Tauvid FDA Approval History

Last updated by Judith Stewart, BPharm on June 25, 2020.

FDA Approved: Yes (First approved May 28, 2020)
Brand name: Tauvid
Generic name: flortaucipir F 18
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diagnosis and Investigation

Tauvid (flortaucipir F 18) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).

Development timeline for Tauvid

May 28, 2020Approval FDA Approves Tauvid (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease
Sep  5, 2018Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.